Effectiveness and Persistency of Ustekinumab Treatment for Ulcerative Colitis: A Phoenix retrospective Cohort Study

被引：4

作者：

Ando, Katsuyoshi ^{[1
]}

Fujiya, Mikihiro ^{[1
]}

Ueno, Nobuhiro ^{[2
]}

Ito, Takahiro ^{[3
]}

Maemoto, Atsuo ^{[3
]}

Nasuno, Masanao ^{[4
]}

Tanaka, Hiroki ^{[4
]}

Sakurai, Kensuke ^{[5
]}

Katsurada, Takehiko ^{[5
]}

Orii, Fumika ^{[6
]}

Ashida, Toshifumi ^{[6
]}

Motoya, Satoshi ^{[7
]}

Kazama, Tomoe ^{[8
]}

Yokoyama, Yoshihiro ^{[8
]}

Hirayama, Daisuke ^{[8
]}

Nakase, Hiroshi ^{[8
]}

机构：

[1] Asahikawa Med Univ, Dept Internal Med, Div Gastroenterol, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan

[2] Asahikawa Med Univ Hosp, Dept Gen Med, Asahikawa, Japan

[3] Sapporo Higashi Tokushukai Hosp, Inflammatory Bowel Dis Ctr, Sapporo, Japan

[4] Sapporo IBD Clin, Sapporo, Japan

[5] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Japan

[6] Sapporo Tokushukai Hosp, Inflammatory Bowel Dis Ctr, Sapporo, Japan

[7] Sapporo Kosei Gen Hosp, IBD Ctr, Sapporo, Japan

[8] Sapporo Med Univ, Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Japan

来源：

CROHNS & COLITIS 360 | 2024年 / 6卷 / 02期

关键词：

ulcerative colitis; ustekinumab; bio-na & iuml; ve; bio-failure; persistency; MAINTENANCE THERAPY; INDUCTION; VEDOLIZUMAB;

D O I：

10.1093/crocol/otae024

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background Real-world data regarding ustekinumab (UST) for ulcerative colitis (UC) particularly in biologics-na & iuml;ve patients is currently limited. This study aimed to elucidate the real-world effectiveness and safety of UST for UC.Methods Overall, 150 patients with UC treated with UST from March 2020 to January 2023 were enrolled across 7 referral hospitals. To assess the clinical efficacy and persistence of UST, retrospective analyses were conducted from weeks 8 to 56. Predictive factors concerning the response and persistence of UST were examined through univariate and multivariate analyses.Results Of the 150 patients, 125 received UST for remission induction, including 36% biologics-na & iuml;ve. The response and remission rates were 72.8% and 56.0% at week 8 and 73.2% and 63.4% at week 56, respectively. Biologics-na & iuml;ve patients represented higher response and remission rates at week 8 (84.4% and 73.3%) than those with biologics exposure (66.2% and 46.2%). Patients with prior antitumor necrosis factor (anti-TNF) and vedolizumab (VDZ) exposure had relatively lower response and remission rates (34.5% and 24.1%, respectively). The 1-year cumulative persistence rate was 84.0%. Multivariate analysis revealed that the chronic continuous type and prior anti-TNF and VDZ exposure were negative predictive factors for week 8 responsiveness. Clinical response at week 8 was a predictor of 1-year persistence. Adverse event incidence remained notably low at 6.4%.Conclusions This study highlights the safety and effectiveness of UST as an induction and maintenance therapy for UC. Chronic continuous type and previous anti-TNF and VDZ exposure negatively contributed to short-term effectiveness, whereas short-term effectiveness provided good persistency. In a retrospective analysis, the use of ustekinumab in ulcerative colitis patients was found to be effective and safe in biologics-na & iuml;ve patients, whereas chronic continuous type ulcerative colitis and prior exposure to anti-TNF and vedolizumab exposure negatively contributed to short-term effectiveness. Graphical Abstract

引用

页数：12

共 32 条

[1] Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension [J].

Abreu, Maria T. ;

Rowbotham, David S. ;

Danese, Silvio ;

Sandborn, William J. ;

Miao, Ye ;

Zhang, Hongyan ;

Tikhonov, Ilia ;

Panaccione, Remo ;

Hisamatsu, Tadakazu ;

Scherl, Ellen J. ;

Leong, Rupert W. ;

Arasaradnam, Ramesh P. ;

Afif, Waqqas ;

Peyrin-Biroulet, Laurent ;

Sands, Bruce E. ;

Marano, Colleen .

JOURNAL OF CROHNS & COLITIS, 2022, 16 (08) :1222-1234

[2] Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study [J].

Amiot, Aurelien ;

Filippi, Jerome ;

Abitbol, Vered ;

Cadiot, Guillaume ;

Laharie, David ;

Serrero, Melanie ;

Altwegg, Romain ;

Bouhnik, Yoram ;

Peyrin-Biroulet, Laurent ;

Gilletta, Cyrielle ;

Roblin, Xavier ;

de Chambrun, Guillaume Pineton ;

Vuitton, Lucine ;

Bourrier, Anne ;

Nancey, Stephane ;

Gornet, Jean-Marc ;

Nahon, Stephane ;

Bouguen, Guillaume ;

Viennot, Stephanie ;

Pariente, Benjamin ;

Fumery, Mathurin .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (11) :1039-1046

[3] Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients [J].

Breidert, Matthias ;

Eftekhari, Pierre ;

Louis, Francois ;

Rotoiu, Claudia ;

Rath, Timo ;

Neurath, Markus F. ;

Atreya, Raja .

CROHNS & COLITIS 360, 2020, 2 (02)

[4] Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry [J].

Chaparro, Maria ;

Garre, Ana ;

Iborra, Marisa ;

Sierra-Ausin, Monica ;

Barreiro-de Acosta, Manuel ;

Fernandez-Clotet, Agnes ;

de Castro, Luisa ;

Bosca-Watts, Maia ;

Jose Casanova, Maria ;

Lopez-Garcia, Alicia ;

Lorente, Rufo ;

Rodriguez, Cristina ;

Carbajo, Ana Y. ;

Teresa Arroyo, Maria ;

Gutierrez, Ana ;

Hinojosa, Joaquin ;

Martinez-Perez, Teresa ;

Villoria, Albert ;

Bermejo, Fernando ;

Busquets, David ;

Camps, Blau ;

Canete, Fiorella ;

Mancenido, Noemi ;

Monfort, David ;

Navarro-Llavat, Merce ;

Lazaro Perez-Calle, Jose ;

Ramos, Laura ;

Rivero, Montserrat ;

Angueira, Teresa ;

Camo Monterde, Patricia ;

Carpio, Daniel ;

Garcia-de-la-Filia, Irene ;

Gonzalez-Munoza, Carlos ;

Hernandez, Luis ;

Huguet, Jose M. ;

Morales, Victor J. ;

Sicilia, Beatriz ;

Vega, Pablo ;

Vera, Isabel ;

Zabana, Yamile ;

Nos, Pilar ;

Suarez Alvarez, Patricia ;

Calvino-Suarez, Cristina ;

Ricart, Elena ;

Hernandez, Vicent ;

Minguez, Miguel ;

Marquez, Lucia ;

Hervias Cruz, Daniel ;

Rubio Iturria, Saioa ;

Barrio, Jesus .

JOURNAL OF CROHNS & COLITIS, 2021, 15 (11) :1846-1851

[5] Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases [J].

Cheng, David ;

Kochar, Bharati D. ;

Cai, Tianxi ;

Ananthakrishnan, Ashwin N. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (10) :2366-+

[6] One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy [J].

Chiappetta, Michele Francesco ;

Viola, Anna ;

Mastronardi, Mauro ;

Turchini, Laura ;

Carparelli, Sonia ;

Orlando, Adele ;

Biscaglia, Giuseppe ;

Miranda, Agnese ;

Guida, Laura ;

Costantino, Giuseppe ;

Scaldaferri, Franco ;

Bossa, Fabrizio ;

Renna, Sara ;

Cappello, Maria ;

Alibrandi, Angela ;

Orlando, Ambrogio ;

Armuzzi, Alessandro ;

Fries, Walter .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (11) :1483-1489

[7] Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis [J].

D'Haens, Geert ;

Dubinsky, Marla ;

Kobayashi, Taku ;

Irving, Peter M. ;

Howaldt, Stefanie ;

Pokrotnieks, Juris ;

Krueger, Kathryn ;

Laskowski, Janelle ;

Li, Xingyuan ;

Lissoos, Trevor ;

Milata, Joe ;

Morris, Nathan ;

Arora, Vipin ;

Milch, Catherine ;

Sandborn, William ;

Sands, Bruce E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (26) :2444-2455

[8] Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis [J].

Feagan, Brian G. ;

Rutgeerts, Paul ;

Sands, Bruce E. ;

Hanauer, Stephen ;

Colombel, Jean-Frederic ;

Sandborn, William J. ;

Van Assche, Gert ;

Axler, Jeffrey ;

Kim, Hyo-Jong ;

Danese, Silvio ;

Fox, Irving ;

Milch, Catherine ;

Sankoh, Serap ;

Wyant, Tim ;

Xu, Jing ;

Parikh, Asit .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08) :699-710

[9] Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study [J].

Fumery, Mathurin ;

Filippi, Jerome ;

Abitbol, Vered ;

Biron, Amelie ;

Laharie, David ;

Serrero, Melanie ;

Altwegg, Romain ;

Bouhnik, Yoram ;

Peyrin-Biroulet, Laurent ;

Gilletta, Cyrielle ;

Roblin, Xavier ;

de Chambrun, Guillaume Pineton ;

Vuitton, Lucine ;

Bourrier, Anne ;

Nancey, Stephane ;

Gornet, Jean-Marc ;

Nahon, Stephane ;

Bouguen, Guillaume ;

Viennot, Stephanie ;

Nachury, Maria ;

Amiot, Aurelien .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (07) :944-951

[10] Response to Anti-α4β7 Blockade in Patients With Ulcerative Colitis Is Associated With Distinct Mucosal Gene Expression Profiles at Baseline [J].

Gazouli, Maria ;

Dovrolis, Nikolas ;

Bourdakou, Marilena M. ;

Gizis, Michalis ;

Kokkotis, Georgios ;

Kolios, George ;

Michalopoulos, Georgios ;

Michopoulos, Spyridon ;

Papaconstantinou, Ioannis ;

Tzouvala, Maria ;

Viazis, Nikos ;

Xourafas, Vasilleios ;

Zacharopoulou, Eirini ;

Zampeli, Evanthia ;

Mantzaris, Gerasimos ;

Papatheodoridis, George ;

Bamias, Giorgos .

INFLAMMATORY BOWEL DISEASES, 2022, 28 (01) :87-95

← 1 2 3 4 →